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Abstract Bayliss and Starling first coined the term ‘hormone’ with reference to secretin, a
substance they found that was produced by the gut, but released into the blood stream to act
at a distance. The intestine is now known as the largest endocrine organ in the body, and it
produces numerous hormones with a wide range of functions. These include controlling appetite
and energy homeostasis. Obesity is one of the greatest health threats facing the world today. At
present, the only successful treatment is surgery. Bariatric procedures such as the Roux-en-Y
bypass work by elevating gut hormones that induce satiety. Significant research has gone into
producing versions of these hormones that can be delivered therapeutically to treat obesity. This
review looks at the role of gut hormones in obesity, and the development of gut hormone-derived
obesity treatments.
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Introduction
Obesity is a problem of balance: too many calories
being consumed, insufficient energy being expended. It
is physiological, i.e. if you didn’t put on weight in the
summer, youmight die in the winter. The bad news is that
it is now ‘summer’ all the time.The statistics for the current
chronic energy imbalance are staggering. The 2013 NHS
report onobesity (TheHealth andSocialCare Information
Centre, 2013) highlights the continuing expansion of the
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nation’s waistline, with 65% of men and 58% of women
being overweight or obese in 2011. The number of hospital
admissions where obesity is the primary diagnosis has
increased11-fold over a decade (The Health and Social
Care Information Centre, 2013). This trend is not limited
to the United Kingdom: World Health Organisation
studies show this is a global phenomenon (Global Health
Observatory, 2008).Obesity has consequences for physical
health, being associated with a rise in cases of diabetes,
strokes and heart attacks, but also has a financial impact,
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through increased use of health services, and reduction in
employment levels. It is estimated that the Actual Total
Costs of Obesity in the UK by 2050 will be £45.5 billion
per year (McPherson et al. 2007). The obese also usually
don’t want to be overweight, and being so can make them
feel miserable.
Current treatments for obesity
Diet, exercise and life-style modifications remain the first
line treatments for obesity. A large meta-analysis has
shown exercise advice alone has, at 6 or 12 months, no
significant impact onbodyweight.While dieting can cause
a5%weight loss at 6months, this drops to3%at48months
(Franz et al. 2007). Combined, diet and exercise has been
reported to cause 8.5% weight loss at 6 months, though
this is limited to 4% by 48 months (Franz et al. 2007).
The surgical treatment of obesity is wellestablished
and highly effective, with weight loss of up to 18% at
20 years after the initial procedure (Picot et al. 2009;
Sjo¨sto¨m, 2013). Consequently a number of clinical bodies
recommend bariatric surgery as the first line treatment
for certain cases of obesity (NICE, 2006; Pories et al. 2010;
Cummings & Cohen, 2014). But bariatric surgery is not
without risk: the mortality rate is between 0.1 and 1.5%
(Buchwald et al. 2007). Furthermore the cost of bariatric
surgery, and the limited number of surgeons performing
it, prevents it being a panacea for the obesity epidemic at
least in the UK.
Pharmacological treatment of obesity within Europe is
limited to orlistat. This is a pancreatic lipase inhibitor
that prevents fat absorption within the gut. However,
its effectiveness is poor, with the average weight loss
being less than 3%, and its use is often accompanied
by debilitating and socially undesirable gastrointestinal
side-effects (Rucker et al. 2007). Other treatments, such
as sibutramine and rimonabant, have been withdrawn
due to psychiatric and cardiovascular effects (Christensen
et al. 2007; James et al. 2010), and new treatments,
notably Qsymia and Belviq, though much feted on their
release, have proven unpopular,due to potentially serious
side-effects, with both regulatory bodies and physicians
in the USA, where they have been granted a licence.
This combination of the inefficacy and concerns over
side-effects, has caused a fall in the number of pre-
scriptions dispensed for the treatment of obesity in recent
years (The Health and Social Care Information Centre,
2013). It is in view of this paucity of viable options that
gut hormones may offer a solution.
Control of appetite
The control of appetite requires the interaction of a
number of different organs and physiological processes
(Fig. 1). Acutely, food consumption is regulated by
activation of gut mechanoreceptors, changes in nutrient
concentration within the plasma, and alteration in gut
hormone levels. Longer term adiposity signals, such as
leptin, also regulate food consumption (Flynn et al.
1998; Farooqi et al. 2007). In addition to these homeo-
static mechanisms, a number of cultural and hedonistic
associations with feeding affect food intake. Neuronal
circuits that control feeding comprise not only traditional
regulatory structures within the brain, such as the hypo-
thalamus and the brainstem, but also the reward pathways
of the cortico-limbic system within the brain (Berthoud,
2012). Gut hormones can influence all of these aspects of
food intake.
Overview of gut hormones that affect energy
homeostasis
The first indication that gut hormones might regulate
appetite was demonstrated in 1937 by N. F. Maclagan.
He was trying to understand the control of appetite and
injected enterogastrone, a crudepreparationof ground-up
intestine, into rabbits. He found that for an hour after
injection, enterogastrone reduced food intake by almost
30% in the animals (Maclagan, 1937).
Thirty years later, Gerard Smith and colleagues started
the first systematic investigation in this area. They under-
took an elegant programme of experiments to look at
the effect of cholecystokinin (CCK) on food intake. They
showed that an intraperitoneal injection of CCK into
fasted rats inhibited food intake by 50% over the first
30 min (Gibbs et al. 1973a). This anorectic effect has since
been replicated in subjects as diverse as sheep and obese
men. Smith’s group then investigated the mechanism
by which CCK stopped eating. The normal behavioural
sequence of rats who feed to satiety is characterised by a
rapid bout of feeding, followed by a period of grooming
and sleeping (Gibbs et al. 1973b). Sham-fed rats, who
have open gastric fistulas, feed continuously, without
showing the behavioural pattern of satiety. Shutting the
fistulas terminates feeding, and elicits the pattern of satiety
behaviour; a single injection of CCK causes the same
pattern of behaviour (Gibbs et al. 1973b). CCK does not
affect the motor aspects of eating (Gibbs et al. 1997), nor
cause any aversion to food, in either rats or man (Kissileff
et al. 1981; Pi-Sunyer et al. 1982; Gibbs et al. 1997).
Together, these results confirm CCK as a physiological
satiety signal. However, other studies question CCK’s
utility as an obesity therapy. Continuous administration
of CCK for 7–14 days using subcutaneous pumps in rats
failed to reduce food intake or body weight compared
to saline controls (Crawley & Beinfeld, 1983). Moreover,
within 4 h of CCK exposure, these rats were resistant to an
acute CCK challenge, at a dose of 5 μg kg–1 that in naive
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Table 1. Summary of gut hormones involved in energy homeostasis
Hormone Peptide family Produced by Activated by Receptors
Cholecystokinin
(CCK)
— L cells in the intestine — CCK1r and CCK2r
Glucagon-like
peptide-1 (GLP-1)
Preproglucagon
derivative
L cells in the intestine — GLP-1r
Glucagon (GCG) Preproglucagon
derivative
α cells of the
pancreas
— GCGr
Oxyntomodulin Preproglucagon
derivative
— — GCGr and GLP-1r
Peptide
tyrosinetyrosine
(PYY)
PP-fold L cells in the intestine DPP-4 Y1, Y2 and Y5 (Y2
specifically when
activated)
Pancreatic
polypeptide (PP)
PP-fold PP cells of the
pancreas
— Y4
Amylin (IAPP) — β cells of the
pancreas
— AMY1a, AMY2a and
AMY3a
Ghrelin — X/A-like cells in the
stomach
GOAT GHSr
rats elicited satiety (Crawley & Beinfeld, 1983). This rapid
development of tolerance to the satiety effects of CCK
limits its therapeutic potential. It has also been shown to
cause both acute pancreatitis and pancreatic cancer.
Since then, a number of other hormones have been
found to signal satiety to the brain. At the same time that
Smith and others were investigating CCK, work by Joel
Habener at Massachussetts General Hospital, and Graeme
Bell and colleagues at Lilly Research Labs in Indianapolis,
led to the discovery of glucagon-like peptide-1(GLP-1).
This is released from the L cells of the small intestine,
produced from the preproglucagon gene. Its role as an
incretin was established early on (Schmidt et al. 1985),
butthe discovery of GLP-1 receptors within the brain
suggested the possibility of functions beyond that of
an incretin. GLP-1administered intracerebroventricularly
(I.C.V.) in rats reduced food intake in a dose-dependent
manner (Turton et al. 1996) (Fig. 2). GLP-1 elicits
the typical satiety pattern of behaviour (Turton et
al. 1996). Jens Holst’s groupadministered GLP-1 via a
subcutaneous infusion to both lean and obese human
subjects, and demonstrated an increase in the sensation
of satiety, a reduction in the sensation of hunger, and a
reduction in caloric intake at a subsequent meal (Flint
et al. 1998; Na¨slund et al. 1999). A meta-analysis by
Verdich et al. confirmed that GLP-1 reduces food intake
in a dose-dependent manner in lean and overweight sub-
jects (Verdich et al. 2001). Importantly, GLP-1 retains
its anorectic effects during chronic exposure. GLP-1
administered at 4.8 pmol kg–1 min for 6 weeks using sub-
cutaneous insulin pumps caused an average loss of 2 kg,
or 2% body weight (Zander et al. 2002).
Like GLP-1, oxyntomodulin is a product of the pre-
proglucagon gene, released from the L cells of the intestine.
It consists of a glucagon molecule with a C-terminal
peptide extension (Bataille et al. 1981b), and can activate
both the glucagon and GLP-1 receptor, albeit more
weakly than either cognate ligand (Baldiserra et al. 1988;
Gros et al. 1993). In line with its activity at the GLP-1
receptor, oxyntomodulin acutely reduces feeding when
Pancreatic Hormones
Gut Hormones Cultural Norms
Palatability/Pleasure of Food
Hypothalamus
Gut Mechanoreceptors
Adiposity Signals
Food  Intake
Figure 1. Diagram of structures involved in control of food intake
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administered both I.C.V. and peripherally in rats. Its
anorectic effects may be mediated by central structures,
as 3 nmol kg–1 of peptide significantly reduced food
intakewhen administered I.C.V. compared to 30 nmol kg−1
when administered peripherally (Dakin et al. 2001, 2004).
Oxyntomodulin also reduces food intake in man: sub-
jects taught to administer 400 nmol of oxyntomodulin
subcutaneously prior to each meal lost an average of
2.4% body weight over 4 weeks, and demonstrated a
reduction in caloric intake at a test meal following
an injection of oxyntomodulin (Wynne et al. 2005).
In addition to reducing food intake, oxyntomodulin
increases energy expenditure. A pair feeding study was
undertaken using three groups of rats: oxyntomodulin
administered I.C.V., an ad libitum-fed saline control group,
and a group administered saline I.C.V., but pair-fed to
the oxyntomodulin group (Dakin et al. 2002). Over
7 days, both the experimental and pair-fed groups
ate identically, but much less than the control group;
however, the experimental group lost significantly more
weight than the pair-fed animals. This finding has
been supported in human studies, where those subjects
who self-administered oxyntomodulin increased their
activity-related energy expenditure by almost 30% over
4 weeks (Wynne et al. 2006). The exact mechanism by
which oxyntomodulin increases energy expenditure has
still to be elucidated; a recent study by Lockie et al.
showed an increase in brown adipose tissue activation
and thermogenesis following acute I.C.V. administration
of oxyntomodulin in mice, which might mediate some
weight loss effects (Lockie et al. 2012). The relative
contributions of the glucagon and GLP-1 receptors to
the effects of oxyntomodulin on food intake and energy
expenditure effects are not firmly established (Baggio
et al. 2004; Pocai et al. 2009; Kosinski et al. 2012;
Lockie et al. 2012). Nevertheless, the dual action of
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Figure 2. Effect of I.C.V. GLP-1 on food intake
Reproduced from Turton et al. (1996) with permission from
Macmillan Publishers Ltd.
oxyntomodulin makes it an attractive target for obesity
therapies.
A third hormone produced by the L cells is peptide
tyrosine tyrosine (PYY).This is amemberof thepancreatic
polypeptide (PP) family, a group containing PP, PYY
and the neurotransmitter neuropeptide Y (NPY), and
defined by a commonhair-pin-fold structure. The PP-fold
peptides act on the Y receptor superfamily. PYY is released
as a 36 residue peptide, PYY(1–36), which can activate
the Y1, Y2 and Y5 receptors; however, it is cleaved to
PYY(3–36) within the plasma by dipeptidyl peptidase
IV (DPP-4); Keire et al. 2000; Kanatani et al. 2000).
Activated PYY levels peak soon after food is ingested,
characteristic of a signal of satiety (Adrian et al. 1985),
and they rise in proportion to the size and caloric content
of the meal consumed (Adrian et al. 1985). Its role
as a satiety signal has been confirmed in vivo. Intra-
peritoneal injections of PYY(3–36) into rats reduced
food intake in a dose-dependent fashion (Batterham
et al. 2002). In humans, a 90 min peripheral infusion of
PYY(3–36) at a dose of 0.8 pmol kg–1 min–1 produced
PYY levels comparable to those seen after eating; this
reduced food intake by 33% over a 24 h period when
compared to the saline control group (Batterham et al.
2002). Obesity is associated with lower fasting levels of
PYY(3–36), and impaired post-prandial secretion of the
hormone (Batterham et al. 2003); however, obesity does
not appear to cause resistance to the action of PYY, as a
similar infusion of PYY(3–36) in obese subjects reduced
food intake by 16% over 24 h (Batterham et al. 2003).
Pancreatic polypeptide is another PP-fold hormone
and satiety signal. It is produced predominantly by the
pancreas, but also in small quantities by the distal gut
(Adrian et al. 1976). Intraperitoneal injections of PP
reduce food intake by almost 50% over a 4 h period in
both lean and obese ob/ob mice (Asakawa et al. 2006).
A randomised, double-blind, cross-over study infusing
saline or pancreatic polypeptide at 10 pmol kg−1 min−1
into healthy human volunteers reduced food intake at a
subsequent buffet meal by 21%, and 24 h food intake by
25% (Batterham et al. b).
Amylin, also known as islet amyloid polypeptide or
IAPP, is a further peptide produced by the pancreas. This
is co-secreted with insulin from the β cells, and cleaved
from an 89 amino-acid prohormone (Sanke et al. 1988).
In addition to its effects on insulin release and glycaemic
control, studies have looked at the effect of amylin on
feeding; these have shown it to have the characteristics of
a satiety signal. Acutely, amylin reduces food intake in rats
over 8 h in a dose-dependent manner (Chance et al. 1991,
1993), and chronic subcutaneous infusions in rats reduced
body weight in a dose-dependent manner (Arnelo et al.
2000). Amylin has a ready propensity to form insoluble
amyloid fibrils, which reduces its solubility, and therefore
prevents easy administration of the native peptide.
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In contrast to the multitude of hormones mentioned
above that suppress appetite, there is only one native
hormone that stimulates food intake. Ghrelin is a 28
amino-acid peptide produced by the X/A-like cells of the
stomach (Date et al. 2000). It is n-octanoylated on the
third residue (Kojima et al. 1999), a reaction catalysed
by the enzyme ghrelin-O-transferase (GOAT) (Yang et al.
2008). Ghrelin binds to the growth hormone secretagogue
receptor (GHSr). Ghrelin levels increase during fasting,
and fall after eating, suggesting that it acts as a signal
to stimulate food intake (Tscho¨p et al. 2000, 2001;
Cummings et al. 2001); indeed, exogenously administered
ghrelin increases food intake in man and rodents (Wren
et al. 2001a, b). Reducing ghrelin levels, or blocking its
effects, may therefore be an alternative strategy to treat
obesity.
Bariatric surgery
Bariatric surgery is a highly effective treatment for obesity.
Surgical techniques canbe loosely divided into twogroups:
those that are purely restrictive in nature, and those
that also contain an element of gastric bypass (Fig. 3).
Restrictive techniques, such as gastric banding, work by
restricting the quantity of food that can be consumed at
any one time. In contrast, bypass surgery alters the normal
pathway for food, so digestion occurs further down the
gut and, since the density of L cells increases with distance
along the small intestine, the release of gut hormones is
greater. The most commonly employed bariatric surgery
technique contains both restrictive and bypass elements.
In a Roux-en-Y gastric bypass, a technique refined from
that described by Mason and Ito in 1969, the stomach is
divided so that only a small proximal pouch exists, which is
then joined to the jejunum. Food therefore bypasses a large
portion of the stomach, the duodenum and proximal part
of the jejunum. The remaining stomach and duodenum
is then itself anastomosed to the jejunum, allowing all
intestinal, biliary and pancreatic secretions to enter the
lower intestine.
The distinction between the restrictive and bypass
surgeries is important: bypass surgery causes greater,
sustained weight loss, and can cause rapid improvement
in diabetes (Rubino et al. 2006; Tice et al. 2008; Colquitt
et al. 2009; Li et al. 2014). Though there is an element
of malabsorption following gastric bypass, which requires
carefulmonitoring of patients’micronutrient intake, over-
all malnutrition, as determined by albumin levels, is not
the cause of weight loss following surgery (Bradley et al.
1977; Odstrcil et al. 2010; Blume et al. 2012). A prospective
study by Griffen et al. (1977) showed a similar amount of
weight loss following aRoux-en-Y bypass to that following
the more malabsorptive procedure of jejunoileal bypass
(JIB), even though the length of bowel bypassed in the
JIB is fourtimes greater (Griffen et al. 1977). Instead, it
is thought that the change in secretion of gut hormones,
in response to changes in the digestive pathway, leads to
the improved weight loss in bypass surgery. Specifically,
post-prandial levels of the satiety signals GLP-1, PYY
and oxyntomodulin are increased (Korner et al. 2009;
Beckman et al. 2010, Laferre`re et al. 2010; Falke´n et al.
2011; Dirksen et al. 2013). The effects of these changes are
twofold. The first is an increase in post-prandial satiety,
which in combination with gastric pouch size restriction,
reduces food intake. The second effect is that the change
in hormonal milieu alters food preference. Kenler et al.
reviewed dietary preferences and caloric intake in patients
pre-operatively, and for 2 years following either horizontal
gastroplasty or Roux-en-Y bypass. The Roux-en-Y group
reduced their overall caloric intake by almost 60%, and
their intake of sweet food by more than 45% (Kenler et al.
1990). Shin et al. looked at rodent models of Roux-en-Y
bypass and compared food preference as measured by a
number of behavioural tests, in surgical, sham-operated,
and control rats. They found that the surgery enhanced the
rats’ liking of low calorie content solutions, and reduced
their preference for high fat or sugar food, in amirroring of
the human studies (Shin et al. 2011). It is this combination
of reduced food intake, and changes in types of food
consumed, that leads to the efficacy of gastric bypass
surgery at causing sustained weight loss.
Gut hormones as an obesity therapy
The efficacy of gut hormones in in vivo and clinical trials,
and their role in mediating the weight loss effects of
bariatric surgery, makes them attractive targets in obesity
therapy. However, there are a number of obstacles to over-
come in the production of a viable anti-obesity drug. As
discussed, obesity therapies have so far been ham-strung
by lack of efficacy and serious side-effects. In developing
peptide therapeutics, Maclagan, in 1937, noted two of
the major limitations: their ‘rather transient’ effects, and
that they are ‘not active by mouth’ (Maclagan, 1937).
These aspects must be addressed to develop an effective
anti-obesity medication.
The half-lives of native gut hormones within the plasma
are limited to a fewminutes due todegradationby enzymes
such as DPP-4 (Schjoldager et al. 1988; Lluis et al. 1989;
Parkes et al.2001). Prolonging the activity of thepeptides is
therefore essential. Thefirst success in this area came about
by chance. John Eng was screening the venom of snakes
and lizards when he isolated a family of peptides from the
saliva of the gilamonster lizard,Heloderma suspectum(Eng
et al. 1992). One of these, exendin-4, has sequence
homology with GLP-1, and similar biological effects
(Raufman et al. 1992). The sequence differences, notably
at the N terminal, render it resistant to degradation by
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DPP-4. These changes extend its half-life from5min to 2 h
(Parkes et al. 2001; Thum et al. 2002). A synthetic version
of exendin-4, exenatide (Byetta), has been formulated,
and has been available as a twice daily injection for the
treatment of diabetes since 2005. Subsequently GLP-1
has been manipulated in other ways to prolong its
half-life, and three other analogues are now available
as diabetes treatments: liraglutide (Victoza) is acetylated
GLP-1; exenatide extended release(Bydureon) is exenatide
incorporated into microspheres, and the recently licensed
albiglutide (Tanzeum) consists of two DPP-4-resistant
human GLP-1 sequences fused to recombinant human
albumin (Matthews et al. 2008).
Another mechanism used to improve hormone activity
is targeted amino acid replacement. A synthetic version of
amylin, pramlintide (Symlin) has been produced in this
way. This has three substituted proline residues, which
stops it forming fibrils. It is stable and soluble (Young
et al. 1996). This has been licensed in the USA as the
first new treatment for type 1 diabetes since insulin in
the 1920s. Targeted amino acid substitution has been
used within our lab to produce gut hormone analogues
whichhaveboth longerhalf-lives than thenativehormone,
and are more potent at causing weight loss. A pancreatic
polypeptide analogue has been through phase 1 clinical
trials (Tan et al. 2012), and a PYY analogue is
undergoing phase 1 trials (ClinicalTrials.gov Identifier:
NCT01515319). Both of these caused significant weight
loss in pre-clinical trials. Targeted substitutions have also
been used to produce oxyntomodulin analogues that are
currently in trials by Thiakis/Pfizer and Zealand Pharma.
PEGylation has been used to prolong the half-life
of gut hormones. The half-life of native PYY is
approximately 8 min within the circulation (Lluis et al.
1989). Conventional PEGylation renders PYY relatively
inactive by preventing receptor binding (Shechter et al.
2005). However, by designing a PEGylated conjugate of
PYY(3–36) wherein the PEG molecule was pH sensitive,
andwould become freed in plasma, Shecter et al.produced
a PYY-related drug which retained the satiety effects of the
native peptide, but with a half-life prolonged tomore than
7 h, and functional activity that led to a 30% reduction
in food intake even 24 h after administration (Shecter
et al. 2005). A similar strategy of reversible PEGylation has
been applied to oxyntomodulin, where a weekly injection
of hormone caused a reduction in food intake of 29%, and
a reduction in body weight of 28% over a 30 day period
(Herskovitz et al. 2013).
Gastric Band
Sleeve Gastrectomy Restrictive
Bypass
Bypass and RestrictiveRoux-en-Y Bypass
Jejuno-ileal Bypass
Restrictive
Figure 3. Types of bypass surgery
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Stable hormonal formulations are therefore possible.
However, this does not guarantee the efficacy of the drug
in clinical practice. It is instructive to look at the efficacy
of the currently available gut hormone medications at
causing weight loss. Licensed for treatment of diabetes,
pramlintide and albiglutide effectively reduce glycosylated
haemoglobin. However, the weight loss they cause is, in
clinical practice, limited. A meta-analysis of pramlintide
suggested weight loss of just over 2 kg over up to 6months
(Singh-Franco et al. 2011); however, subgroup analysis
showed that weight loss at the maximum licensed dose
of 120 μg was only 1.8 kg, and that greater weight loss
was seen at doses of 150–360 μg (Singh-Franco et al.
2011). Following 16 weeks of albiglutide therapy, weight
loss in subjects failed to reach statistical significance,
ranging between −1.1 and −1.7 kg, compared to −0.7 kg
in the control group. Exenatide and liraglutide fare
better:meta-analyses of both have shown that they do
cause significant weight loss over periods ranging between
4 and 26 weeks, with absolute weight loss of up to 6 kg
over the study periods (Norris et al. 2009; Niswender
et al. 2013). However, as with pramlintide, greater degrees
of weight loss are seen at higher drug doses, often
above those currently licensed. Astrup et al. under-
took a randomised, double-blind, placebo-controlled,
multinational study using liraglutide. After 1 year, those
on the maximum licensed dose (1.2 mg daily) had lost
an average 3.8 kg, which was non-significant; however,
significant weight loss was achieved in those on 1.8 mg or
more of liraglutide daily, to a maximum of 7.8 kg weight
loss after 1 year in those on 3.0mg daily of liraglutide. This
went up to 10.3 ± 7.1 kg weight loss over 2 years from
screening (Astrup et al. 2012). As such, the manufacturers
of liraglutide, Novo Nordisk, have recently filed with the
US Food and Drug Administration (FDA)for high-dose
3 mg liraglutide to be licensed as an obesity therapy.
Effective obesity therapies are often beset with
problematic side-effects. All GLP-1 agonists are associated
with nausea. More than 50% of subjects receiving 3 mg
daily of liraglutide complained of nausea and vomiting,
and though in the majority of cases this was mild or
moderate, and tended to be transient, 4% did withdraw
from the trial because of this (Astrup et al. 2012). In the
albiglutide trial, more than 50% of subjects experienced
nausea at higher doses (Rosenstock et al. 2009). Nausea
arises from rapid increases in plasma levels of peptides.
One strategy to overcome this has been continuous
administration of GLP-1 for one year via an implanted
minipump; this is so far well tolerated, and is undergoing
phase III clinical trials as a treatment for diabetes (Henry
et al. 2014; www.intarcia.com).
Rapid increases in plasma peptide levels, and the
ensuantnausea, have also scuppereddevelopmentof aPYY
therapy. Merck and Nastech Pharmaceutical produced a
nasal spray formulation of PYY, hoping to make the route
of administration more acceptable than subcutaneous
injections. However, the swift absorption through the
nasal membrane led to rapid peaks in plasma levels.
Seventy-eight per cent of subjects receiving 600 μg three
times a day experienced nausea, and almost 50% of
the same group suffered from vomiting, so more than
60% of subjects discontinued therapy at this dose (Gantz
et al. 2007). Despite these gastrointestinal side-effects,
this dose did not produce significant weight loss (Gantz
et al. 2007). Osmotic mini-pumps have been used to
deliver PYY continuously in rodent studies, which could
limit peaks in plasma levels and limit nausea; however,
these only produce a transient reduction in food intake,
suggesting the possibility that tolerance could develop to
PYY delivered in this way (Adams et al. 2006).
Side-effects have also limited development of
CCK-based treatments. CCK, initially known as
cholecystokinin-pancreozymin, increases amylase
secretion (Banwell et al. 1967), and can cause acute
pancreatitis (Niederau et al. 1986). It also has potential
role in the development of pancreatic cancer:CCK
causes pancreatic acinar cell proliferation via the
MAPK/c-Jun/AP-1 pathway (Guo et al. 2012), and
can increase cell numbers in certain pancreatic cancer
cell lines (Ohlsson et al. 1999). Such concerns make
development of CCK-based therapies unlikely. Similar
concerns about pancreatitis and pancreatic cancer have
recently been raised about GLP-1 analogues; however,
large-scale reviews by both the FDA and the European
Medicines Agency (EMA) have failed to find any firm
evidence of such in spite of considerable animal testing
and human experience (Egan et al. 2014).
All currently available gut hormone preparations
require subcutaneous injection, as peptides are digested
in the stomach and intestine. A number of groups have
nevertheless tried todeveloporal formulations.GLP-1 and
PYYhavebeen conjugatedwith vitaminB12,with a view to
using thehighly effectiveB12uptake system in the stomach
to facilitate peptide absorption; however, no feeding
studieshaveyetbeenperformedwith thesepeptides (Fazen
et al. 2011; Clardy-James et al. 2013). Another delivery
agent, used by Christoph Beglinger’s group in Basel, is
sodium N-[8-(2-hydroxybenzoyl) amino]caprylate), or
SNAC. This enhances the lipophilicity of the peptides,
enabling them to be transported across the intestinal
epithelium. Once in the plasma the delivery molecule
and drug dissociate (Beglinger et al. 2008). Ingestion
of SNAC–GLP-1, or SNAC–GLP-1 in combination with
SNAC–PYY, reduce food intake at a test meal in healthy
volunteers by up to 20%, though with notable variability
between subjects (Steinert et al. 2010). Furthermore, a
single dose produced no change in food consumption
over a 24 h period, and 2 of the 12 subjects suffered
gastrointestinal side-effects during co-administration of
the peptides (Steinert et al. 2010).
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As ghrelin works to increase food intake, it has to be
targeted in different ways to the above satiety signals.
Approacheshave includedantagonists and inverse agonists
at the ghrelin receptor, neutralisation of ghrelin through
vaccines or Spiegelmers (single-stranded mirror image
oligonucleotides), and through reducing levels of activated
ghrelin by targeting the enzyme GOAT. The success of
these strategies has been varied. Some ghrelin antagonists
reduced body weight in rats by 15% (Esler et al. 2007),
though others which worked in vitro caused an increased
body weight in vivo (Halem et al. 2005). Rats who
developed antibodies against their own ghrelin through
inoculation with a ghrelin hapten showed reduced body
weight gain, though daily food intake did not change
(Zorrilla et al. 2006), but a vaccine trial in man by Cyto
Biotechnology caused no significant weight loss in obese
subjects. GOAT inhibitors reduced weight gain in lean
mice (Barnett et al. 2010), but are unlikely to help in obese
subjects as ghrelin levels are already suppressed (Homaee
et al. 2011). Though the ghrelin system is being targeted in
clinical trials to treat other conditions (Alize Pharma have
started trials of AZP-531, an unacylated ghrelin analogue,
to treat diabetes, and Rhythm has a ghrelin analogue,
RM-131, in phase II trials to treat gastroparesis), we are
unaware of any clinical trials at present that are targeting
the ghrelin system to treat obesity. Since ghrelin is low in
obesity it might be that it is autosuppressed and further
suppression is ineffective.
Medical bypass
Significant side-effects and modest weight loss mean a
single hormone therapy is unlikely to be the solution
to the obesity pandemic. Following gastric bypass, it
is the increased secretion of multiple gut hormones
that appears to be effective. There is also increasing
evidence that gut hormones interact and augment each
other’s effects. Intraperitoneal injections of PYY(3–36)
enhanced glucose-stimulated GLP-1 levels within the
hepatic portal vein (although systemic GLP-1 levels
remained unchanged) (Chandarana et al. 2013), while
cholecystokinin stimulates isolated neurons that produce
GLP-1 within the brain via an increase in glutaminergic
synaptic activity (Hisadome et al. 2011). Therefore,
emulating the success of bariatric surgery means targeting
multiple gut hormone pathways simultaneously.
Oxyntomodulin is a naturally occurring dual agonist
at the glucagon and GLP-1 receptor and a number of
studies have shown that activation of both receptors
improves weight loss effects compared to single receptor
activation (Pocai et al. 2009; Day et al. 2009, 2012).
Co-administration of two separate native peptides has also
been investigated. Neary et al. administered very low dose
GLP-1 and PYY(3–36) either alone or in combination
to rats; though at these concentrations alone neither
hormone reduced food intake, when combined, food
intake was significantly reduced for 4 h (Neary et al.
2005). A similar pattern was seen following infusion of
GLP-1 and PYY(3–36) in human volunteers: GLP-1 at
0.4 pmol kg−1 min−1 had no significant effect on food
intake, while PYY at 0.4 pmol kg−1 min−1 reduced food
intake by 15%; however, when both peptides were infused,
food intake at a subsequent buffet meal was reduced by
27%, and also significantly reduced over the following
24 h, without causing increased nausea (Neary et al.
2005). Similarly, Shi et al. showed that PYY(3–36) and
pancreatic polypeptide, administered at anorectic doses
(47 nmol kg–1 of pancreatic polypeptide and 74 nmol kg–1
of PYY), had an additive effect on reducing food intake
in mice. However, the synergistic effect of peptides is dose
dependent. Thus, at subanorectic doses of PP and PYY
(30 nmol kg−1 of each peptide), co-administration did
not significantly reduce food intake in mice (Neary et al.
2008); furthermore, when the two peptides were infused
into humans at subanorectic doses, food intake actually
increased in the co-administration group compared to
either peptide alone (Neary et al. 2008).
Single drugs that target multiple gut hormones have
been or are in development. A synthetic peptide with
properties of both PYY and PP, obinepitide, had been
developed by 7TMpharma, and was reported to show
promising results in early clinical trials. Development
at the moment has been shelved as it was not that
effective. An alternative approach includes administering
two stable formulations of different peptides together; as
such, a single injection containing a PYY analogue and an
oxyntomodulin analogue which activates the Y2, GLP-1
and glucagon receptor has been shown to cause significant
weight loss in pre-clinical trials, andwill soon enter phase I
clinical trials (S. R. Bloom, unpublished observations).
Conclusion
Gut hormones have provided a focus in obesity research
for more than 40 years. It is now possible to reliably
make a fat mouse thin. Under clinical trial conditions,
gut hormones can help reduce appetite and cause weight
loss in man. Stable peptide preparations are available
and in wide clinical use in the treatment of diabetes,
and many gut hormone analogues are entering clinical
trials and show a great deal of promise. However, at pre-
sent, there is no simple solution to the obesity pandemic.
Gut hormones may provide an effective medical solution
in time. Meanwhile, we are beholden to the memory of
Bayliss and Starling, and all those people world-wide who
suffer from obesity, to persevere within this field until a
solution is found.
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